KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Current Liabilities (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Total Current Liabilities data on record, last reported at $120.6 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 61.09% year-over-year to $120.6 million; the TTM value through Dec 2025 reached $120.6 million, down 61.09%, while the annual FY2025 figure was $120.6 million, 61.09% down from the prior year.
  • Total Current Liabilities reached $120.6 million in Q4 2025 per PCRX's latest filing, up from $107.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $521.1 million in Q4 2021 and bottomed at $92.7 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $199.1 million, with a median of $140.5 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: tumbled 71.64% in 2022, then surged 237.86% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $521.1 million in 2021, then crashed by 71.64% to $147.8 million in 2022, then plummeted by 34.1% to $97.4 million in 2023, then surged by 218.25% to $309.9 million in 2024, then plummeted by 61.09% to $120.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $120.6 million in Q4 2025, $107.1 million in Q3 2025, and $313.2 million in Q2 2025.